Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	zinc ion binding	RNF217 KMT2A NR1H2 ZMYM4 ESRRB ESRRG USP33 ZMYND8	1.19e-06	891	20	8	GO:0008270
GeneOntologyMolecularFunction	transition metal ion binding	RNF217 KMT2A NR1H2 ZMYM4 ESRRB ESRRG USP33 ZMYND8	1.02e-05	1189	20	8	GO:0046914
GeneOntologyMolecularFunction	nuclear receptor activity	NR1H2 ESRRB ESRRG	2.84e-05	60	20	3	GO:0004879
GeneOntologyMolecularFunction	ligand-activated transcription factor activity	NR1H2 ESRRB ESRRG	2.98e-05	61	20	3	GO:0098531
GeneOntologyMolecularFunction	estrogen response element binding	ESRRB ESRRG	5.21e-05	11	20	2	GO:0034056
GeneOntologyMolecularFunction	nuclear steroid receptor activity	ESRRB ESRRG	2.82e-04	25	20	2	GO:0003707
GeneOntologyMolecularFunction	lysine-acetylated histone binding	KMT2A ZMYND8	4.08e-04	30	20	2	GO:0070577
GeneOntologyMolecularFunction	acetylation-dependent protein binding	KMT2A ZMYND8	4.36e-04	31	20	2	GO:0140033
GeneOntologyMolecularFunction	protein tyrosine/serine/threonine phosphatase activity	CDC14C CDC14B	8.40e-04	43	20	2	GO:0008138
GeneOntologyMolecularFunction	histone modifying activity	KMT2A KDM4B RNF20	1.47e-03	229	20	3	GO:0140993
GeneOntologyMolecularFunction	histone binding	KMT2A ZMYND8 RNF20	2.23e-03	265	20	3	GO:0042393
GeneOntologyMolecularFunction	DNA-binding transcription factor binding	KMT2A NR1H2 ESRRB ZMYND8	2.39e-03	582	20	4	GO:0140297
GeneOntologyMolecularFunction	myosin phosphatase activity	CDC14C CDC14B	3.24e-03	85	20	2	GO:0017018
GeneOntologyMolecularFunction	protein tyrosine phosphatase activity	CDC14C CDC14B	4.71e-03	103	20	2	GO:0004725
GeneOntologyMolecularFunction	protein serine/threonine phosphatase activity	CDC14C CDC14B	5.26e-03	109	20	2	GO:0004722
GeneOntologyMolecularFunction	transcription factor binding	KMT2A NR1H2 ESRRB ZMYND8	6.00e-03	753	20	4	GO:0008134
GeneOntologyMolecularFunction	steroid binding	ESRRB ESRRG	7.73e-03	133	20	2	GO:0005496
Domain	Oest-rel_rcp	ESRRB ESRRG	2.94e-06	3	19	2	IPR027289
Domain	Oest_rcpt/oest-rel_rcp	ESRRB ESRRG	9.79e-06	5	19	2	IPR024178
Domain	zf-C4	NR1H2 ESRRB ESRRG	1.32e-05	46	19	3	PF00105
Domain	NUCLEAR_REC_DBD_1	NR1H2 ESRRB ESRRG	1.32e-05	46	19	3	PS00031
Domain	Znf_hrmn_rcpt	NR1H2 ESRRB ESRRG	1.32e-05	46	19	3	IPR001628
Domain	Nuclear_hrmn_rcpt	NR1H2 ESRRB ESRRG	1.32e-05	46	19	3	IPR001723
Domain	ZnF_C4	NR1H2 ESRRB ESRRG	1.32e-05	46	19	3	SM00399
Domain	NUCLEAR_REC_DBD_2	NR1H2 ESRRB ESRRG	1.32e-05	46	19	3	PS51030
Domain	-	NR1H2 ESRRB ESRRG	1.41e-05	47	19	3	1.10.565.10
Domain	HOLI	NR1H2 ESRRB ESRRG	1.50e-05	48	19	3	SM00430
Domain	Nucl_hrmn_rcpt_lig-bd	NR1H2 ESRRB ESRRG	1.50e-05	48	19	3	IPR000536
Domain	Hormone_recep	NR1H2 ESRRB ESRRG	1.50e-05	48	19	3	PF00104
Domain	-	NR1H2 ESRRB ESRRG	2.52e-05	57	19	3	3.30.50.10
Domain	Znf_NHR/GATA	NR1H2 ESRRB ESRRG	2.66e-05	58	19	3	IPR013088
Domain	Retinoid-X_rcpt/HNF4	ESRRB ESRRG	4.39e-05	10	19	2	IPR000003
Domain	PHD	KMT2A KDM4B ZMYND8	5.75e-05	75	19	3	PF00628
Domain	-	KMT2A KDM4B USP33 ZMYND8 RNF20	6.91e-05	449	19	5	3.30.40.10
Domain	Znf_RING/FYVE/PHD	KMT2A KDM4B USP33 ZMYND8 RNF20	7.67e-05	459	19	5	IPR013083
Domain	PHD	KMT2A KDM4B ZMYND8	9.59e-05	89	19	3	SM00249
Domain	Znf_PHD	KMT2A KDM4B ZMYND8	1.02e-04	91	19	3	IPR001965
Domain	ZF_PHD_2	KMT2A KDM4B ZMYND8	1.16e-04	95	19	3	PS50016
Domain	ZF_PHD_1	KMT2A KDM4B ZMYND8	1.20e-04	96	19	3	PS01359
Domain	EPHD	KMT2A KDM4B	2.24e-04	22	19	2	PS51805
Domain	Znf_FYVE_PHD	KMT2A KDM4B ZMYND8	4.22e-04	147	19	3	IPR011011
Domain	BROMODOMAIN_2	KMT2A ZMYND8	7.85e-04	41	19	2	PS50014
Domain	BROMO	KMT2A ZMYND8	8.24e-04	42	19	2	SM00297
Domain	Bromodomain	KMT2A ZMYND8	8.24e-04	42	19	2	IPR001487
Domain	-	KMT2A ZMYND8	8.24e-04	42	19	2	1.20.920.10
Domain	Znf_PHD-finger	KMT2A ZMYND8	2.88e-03	79	19	2	IPR019787
Domain	Pkinase_Tyr	MLKL PTK7	7.50e-03	129	19	2	PF07714
Domain	Ser-Thr/Tyr_kinase_cat_dom	MLKL PTK7	8.54e-03	138	19	2	IPR001245
Domain	Prot_kinase_dom	MLKL PTK7 GRK1	1.27e-02	489	19	3	IPR000719
Domain	PROTEIN_KINASE_DOM	MLKL PTK7 GRK1	1.29e-02	493	19	3	PS50011
Pathway	REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY	NR1H2 ESRRB ESRRG	2.44e-05	48	17	3	MM14987
Pathway	REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY	NR1H2 ESRRB ESRRG	3.29e-05	53	17	3	M8276
Pathway	WP_NUCLEAR_RECEPTORS	NR1H2 ESRRB	9.38e-04	38	17	2	MM15865
Pathway	WP_NUCLEAR_RECEPTORS	NR1H2 ESRRB	9.38e-04	38	17	2	M39657
Pubmed	ERR2 and ERR3 promote the development of gamma motor neuron functional properties required for proprioceptive movement control.	GFRA1 ESRRB ESRRG	4.16e-08	12	21	3	36542664
Pubmed	Identification of two hERR2-related novel nuclear receptors utilizing bioinformatics and inverse PCR.	ESRRB ESRRG	3.47e-07	2	21	2	10072763
Pubmed	Expression of estrogen-related receptors in ovarian cancer and impact on survival.	ESRRB ESRRG	3.47e-07	2	21	2	34089362
Pubmed	An ERRbeta/gamma agonist modulates GRalpha expression, and glucocorticoid responsive gene expression in skeletal muscle cells.	ESRRB ESRRG	3.47e-07	2	21	2	19631715
Pubmed	Overexpression of CDC14B causes mitotic arrest and inhibits zygotic genome activation in mouse preimplantation embryos.	CDC14C CDC14B	3.47e-07	2	21	2	19923902
Pubmed	The Cdc14B phosphatase displays oncogenic activity mediated by the Ras-Mek signaling pathway.	CDC14C CDC14B	3.47e-07	2	21	2	21502810
Pubmed	Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.	KMT2A RNF20	3.47e-07	2	21	2	23412334
Pubmed	Birth and rapid subcellular adaptation of a hominoid-specific CDC14 protein.	CDC14C CDC14B	3.47e-07	2	21	2	18547142
Pubmed	Early-onset aging and defective DNA damage response in Cdc14b-deficient mice.	CDC14C CDC14B	1.04e-06	3	21	2	21262768
Pubmed	Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues.	ESRRB ESRRG	1.04e-06	3	21	2	15598686
Pubmed	Cdc14b regulates mammalian RNA polymerase II and represses cell cycle transcription.	CDC14C CDC14B	1.04e-06	3	21	2	22355704
Pubmed	Estrogen-Related Receptors Mediate the Adaptive Response of Brown Adipose Tissue to Adrenergic Stimulation.	ESRRB ESRRG	1.04e-06	3	21	2	29888756
Pubmed	CDC14B acts through FZR1 (CDH1) to prevent meiotic maturation of mouse oocytes.	CDC14C CDC14B	1.04e-06	3	21	2	19129509
Pubmed	Cdc14A and Cdc14B Redundantly Regulate DNA Double-Strand Break Repair.	CDC14C CDC14B	1.04e-06	3	21	2	26283732
Pubmed	CDC14A phosphatase is essential for hearing and male fertility in mouse and human.	CDC14C CDC14B	2.08e-06	4	21	2	29293958
Pubmed	Target specificities of estrogen receptor-related receptors: analysis of binding sequences and identification of Rb1-inducible coiled-coil 1 (Rb1cc1) as a target gene.	ESRRB ESRRG	2.08e-06	4	21	2	18039682
Pubmed	Estrogen-related receptors alpha, beta and gamma expression and function is associated with transcriptional repressor EZH2 in breast carcinoma.	ESRRB ESRRG	2.08e-06	4	21	2	29940916
Pubmed	Mis12 controls cyclin B1 stabilization via Cdc14B-mediated APC/CCdh1 regulation during meiotic G2/M transition in mouse oocytes.	CDC14C CDC14B	2.08e-06	4	21	2	32341029
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	KMT2A NR1H2 KDM4B ESRRB ESRRG ZMYND8	2.94e-06	709	21	6	22988430
Pubmed	Involvement of estrogen-related receptors in transcriptional response to hypoxia and growth of solid tumors.	ESRRB ESRRG	3.47e-06	5	21	2	18509053
Pubmed	Nuclear receptor/microRNA circuitry links muscle fiber type to energy metabolism.	ESRRB ESRRG	3.47e-06	5	21	2	23676496
Pubmed	Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases.	ESRRB ESRRG	5.20e-06	6	21	2	21177257
Pubmed	Receptor-interacting protein 140 differentially regulates estrogen receptor-related receptor transactivation depending on target genes.	ESRRB ESRRG	5.20e-06	6	21	2	16439465
Pubmed	Peroxisome proliferator-activated receptor γ coactivator 1 (PGC-1)- and estrogen-related receptor (ERR)-induced regulator in muscle 1 (Perm1) is a tissue-specific regulator of oxidative capacity in skeletal muscle cells.	ESRRB ESRRG	5.20e-06	6	21	2	23836911
Pubmed	Perm1 promotes cardiomyocyte mitochondrial biogenesis and protects against hypoxia/reoxygenation-induced damage in mice.	ESRRB ESRRG	1.25e-05	9	21	2	34029594
Pubmed	Wnt7A identifies embryonic γ-motor neurons and reveals early postnatal dependence of γ-motor neurons on a muscle spindle-derived signal.	GFRA1 ESRRG	1.90e-05	11	21	2	22723712
Pubmed	NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency.	KMT2A ZMYM4 ZMYND8	3.23e-05	103	21	3	32744500
Pubmed	A dynamic expression survey identifies transcription factors relevant in mouse digestive tract development.	NR1H2 ESRRB ESRRG	4.84e-05	118	21	3	16971476
Pubmed	Transcriptome analysis of mouse stem cells and early embryos.	CDC14C CDC14B USP33 ZMYND8	6.07e-05	363	21	4	14691545
Pubmed	Meta-analysis identifies four new loci associated with testicular germ cell tumor.	MLKL LIPG	6.55e-05	20	21	2	23666239
Pubmed	Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition.	KMT2A KDM4B	7.24e-05	21	21	2	27626377
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	KMT2A ZMYM4 KDM4B ZMYND8 RNF20	8.16e-05	774	21	5	15302935
Pubmed	Cartilage-specific overexpression of ERRγ results in Chondrodysplasia and reduced chondrocyte proliferation.	ESRRB ESRRG	8.72e-05	23	21	2	24349082
Pubmed	Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst.	NR1H2 KDM4B ESRRB ESRRG ZMYND8	9.98e-05	808	21	5	20412781
Pubmed	Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.	KMT2A CDC14B ZMYM4	1.13e-04	157	21	3	30686591
Pubmed	Direct reprogramming of fibroblasts into renal tubular epithelial cells by defined transcription factors.	ESRRB ESRRG	2.41e-04	38	21	2	27820600
Pubmed	Genomic analysis of mouse retinal development.	KMT2A ZMYM4 ESRRB USP33 RNF20	2.77e-04	1006	21	5	15226823
Pubmed	TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation.	ZMYM4 ZMYND8 RNF20	3.05e-04	220	21	3	35785414
Pubmed	Single-cell profiling of epigenetic modifiers identifies PRDM14 as an inducer of cell fate in the mammalian embryo.	KMT2A KDM4B	3.24e-04	44	21	2	24183668
Pubmed	Identification of Jmjd3 as an Essential Epigenetic Regulator of Hox Gene Temporal Collinear Activation for Body Axial Patterning in Mice.	KMT2A KDM4B	4.01e-04	49	21	2	34368113
Pubmed	Screening large numbers of expression patterns of transcription factors in late stages of the mouse thymus.	NR1H2 ESRRB ESRRG	5.14e-04	263	21	3	20932939
Pubmed	Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.	KMT2A ZMYND8 RNF20	5.43e-04	268	21	3	33640491
Pubmed	New nomenclature for chromatin-modifying enzymes.	KMT2A KDM4B	5.43e-04	57	21	2	18022353
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	KMT2A USP33 PTK7 RNF20	5.62e-04	650	21	4	38777146
Pubmed	Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease.	LIPG NR1H2	5.82e-04	59	21	2	20855565
GeneFamily	Nuclear hormone receptors	NR1H2 ESRRB ESRRG	1.02e-05	49	16	3	71
GeneFamily	PHD finger proteins	KMT2A ZMYND8	2.81e-03	90	16	2	88
GeneFamily	Ring finger proteins	RNF217 RNF20	2.40e-02	275	16	2	58
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Medullary_Thick_Ascending_Limb_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ESRRB ESRRG ZMYND8	6.94e-05	172	21	3	1565f38266891c3acf49778838de134c5dee5460
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Degenerative_Distal_Convoluted_Tubule_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ESRRB RPL37A ESRRG	7.56e-05	177	21	3	dc846d0feb94d4c289553cc3ac9dac81d10409cb
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Medullary_Thick_Ascending_Limb_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ESRRB ESRRG ZMYND8	7.94e-05	180	21	3	9e09b3dfe344b5d50520711513d389865d73a861
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Medullary_Thick_Ascending_Limb_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ESRRB ESRRG ZMYND8	8.21e-05	182	21	3	041bc819e6cf2618bf86bce8dfe2df673f392ba3
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ESRRB ESRRG ZMYND8	8.34e-05	183	21	3	31ab55d5f3639f5964541d5eae23044dbda3356e
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ESRRB ESRRG ZMYND8	8.61e-05	185	21	3	898a093757f86be3e18d2ef1f16a71f50ef81dc3
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	LIPG ESRRB ESRRG	8.89e-05	187	21	3	f124d2c699b717b7c02a1a70493f515b83dc2f4c
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	LIPG ESRRB ESRRG	8.89e-05	187	21	3	77886f99c229610abd28c4c370d2c7d1536c9782
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Macula_Densa_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	LIPG ESRRG PTK7	9.18e-05	189	21	3	e059be2965cca70ff5576df055d0af1775b76e00
ToppCell	renal_medulla_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	ESRRB ESRRG ZMYND8	9.18e-05	189	21	3	830d9cd0dd706bce22eb2416f07b2c31c870a05a
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	LIPG ESRRB ESRRG	9.18e-05	189	21	3	e32172ad09e93f6ac6ea2b92145b2b73003f7970
ToppCell	PCW_07-8.5-Endothelial-Endothelial_immature-endo_immature_venous_(4)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	MLKL LIPG LINC00305	1.01e-04	195	21	3	ca2cf2c10db1ad17aa0a2e30aa7079a7ad751ea6
ToppCell	COVID-19-kidney-TAL\|kidney / Disease (COVID-19 only), tissue and cell type	ESRRB ESRRG PTK7	1.02e-04	196	21	3	04f5eb206ed3016a737609a3ebac0c1fcabb94ef
ToppCell	facs-Bladder-nan-3m\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RPL37A PTK7 ZMYND8	1.02e-04	196	21	3	44f5b1b474399c9316729155f2ea95a82ca66e30
ToppCell	facs-Bladder-nan-3m-Epithelial\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RPL37A PTK7 ZMYND8	1.02e-04	196	21	3	c0e90d964baa2eb4fbd18a52379ccec5d3bf59a8
Computational	RTK signaling.	PTK7 GRK1	9.62e-04	46	11	2	MODULE_259
Computational	Genes upregulated in subsets of cells of a given type within various tumors	KMT2A ZMYM4	1.14e-03	50	11	2	GAVISH_3CA_MALIGNANT_METAPROGRAM_4_CHROMATIN
Computational	Genes in the cancer module 199.	PTK7 GRK1	1.47e-03	57	11	2	MODULE_199
Drug	N'-((1E)-(4-(diethylamino)phenyl)methylene)-4-hydroxybenzohydrazide	ESRRB ESRRG	8.10e-07	2	21	2	ctd:C501618
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	CDC14B LIPG KDM4B ESRRG	2.36e-05	187	21	4	6709_UP
Drug	Azaguanine-8 [134-58-7]; Down 200; 26.2uM; MCF7; HT_HG-U133A	KMT2A ZMYM4 KDM4B ZMYND8	2.73e-05	194	21	4	1670_DN
Drug	Butamben [94-25-7]; Up 200; 20.6uM; PC3; HT_HG-U133A	LIPG GFRA1 ESRRG ZMYND8	2.90e-05	197	21	4	5792_UP
Drug	U23,469	ESRRB ESRRG	2.91e-05	9	21	2	CID000161922
Drug	ketononestrol aziridine	ESRRB ESRRG	6.28e-05	13	21	2	CID000130642
Drug	2-phenylindole	ESRRB ESRRG	6.28e-05	13	21	2	CID000013698
Drug	benzophenone-2	ESRRB ESRRG	8.45e-05	15	21	2	CID000008571
Drug	AC1Q7B2S	ESRRB ESRRG	8.45e-05	15	21	2	CID000015019
Drug	TAT-59	ESRRB ESRRG	9.65e-05	16	21	2	CID003034829
Drug	OH-PCB 30	ESRRB ESRRG	9.65e-05	16	21	2	CID000105036
Drug	AC1L1KIN	NR1H2 ESRRB ESRRG	1.03e-04	100	21	3	CID000005516
Drug	E-guggulsterone	NR1H2 ESRRB ESRRG	1.30e-04	108	21	3	CID006439929
Drug	AC1L2JTN	ESRRB ESRRG	1.68e-04	21	21	2	CID000022150
Drug	indenestrol A	ESRRB ESRRG	1.68e-04	21	21	2	CID000107664
Drug	tamoxifen aziridine	ESRRB ESRRG	1.85e-04	22	21	2	CID003033894
Drug	indenestrol B	ESRRB ESRRG	1.85e-04	22	21	2	CID000114716
Drug	idoxifene	ESRRB ESRRG	2.80e-04	27	21	2	CID003034011
Drug	nafoxidine	ESRRB ESRRG	2.80e-04	27	21	2	CID000004416
Drug	RU 16117	ESRRB ESRRG	3.02e-04	28	21	2	CID000066408
Drug	dihydroequilenin	ESRRB ESRRG	3.02e-04	28	21	2	CID000003247
Drug	MCDF	ESRRB ESRRG	3.02e-04	28	21	2	CID000114900
Drug	CDRI-85/287	ESRRB ESRRG	3.24e-04	29	21	2	CID000159508
Drug	hexestrol	ESRRB ESRRG	3.24e-04	29	21	2	CID000003606
Drug	Tl-I	ESRRB ESRRG	3.24e-04	29	21	2	CID006432721
Drug	LY117018	ESRRB ESRRG	3.24e-04	29	21	2	CID000104946
Drug	alpha-zearalanol	ESRRB ESRRG	3.24e-04	29	21	2	CID000022283
Drug	butyl benzyl phthalate	ESRRB ESRRG	3.95e-04	32	21	2	CID000002347
Drug	schizandrin	ESRRB ESRRG	3.95e-04	32	21	2	CID000023915
Drug	o,p'-DDE	ESRRB ESRRG	3.95e-04	32	21	2	CID000246598
Drug	RU 58668	ESRRB ESRRG	4.20e-04	33	21	2	CID000119604
Drug	AC1L1K7W	ESRRB ESRRG	4.47e-04	34	21	2	CID000005377
Drug	formononetin	ESRRB ESRRG	4.47e-04	34	21	2	CID005280378
Drug	centchroman	ESRRB ESRRG	4.47e-04	34	21	2	CID000035805
Drug	AC1L32HG	ESRRB ESRRG	4.47e-04	34	21	2	CID000107645
Drug	Id-5	ESRRB ESRRG	5.01e-04	36	21	2	CID000448658
Drug	anastrozole	ESRRB ESRRG	5.29e-04	37	21	2	CID000002187
Drug	A 5791	ESRRB ESRRG	5.29e-04	37	21	2	CID000003408
Drug	Piperlongumine [20069-09-4]; Down 200; 12.6uM; HL60; HG-U133A	AKAP11 RPL37A ZMYND8	5.73e-04	179	21	3	1764_DN
Drug	Captopril [62571-86-2]; Down 200; 17.2uM; PC3; HT_HG-U133A	KMT2A CDC14B KDM4B	5.73e-04	179	21	3	4585_DN
Drug	Adiphenine hydrochloride [50-42-0]; Down 200; 11.4uM; MCF7; HT_HG-U133A	KMT2A KDM4B ZMYND8	6.11e-04	183	21	3	1709_DN
Drug	fadrozole	ESRRB ESRRG	6.19e-04	40	21	2	CID000059693
Drug	arzoxifene	ESRRB ESRRG	6.19e-04	40	21	2	CID000179337
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A	KDM4B RPL37A ZMYND8	6.20e-04	184	21	3	2321_DN
Drug	d-equilenin	ESRRB ESRRG	6.50e-04	41	21	2	CID000010597
Drug	Goserelin	ESRRB ESRRG	6.50e-04	41	21	2	CID000047725
Drug	Cantharidin [56-25-7]; Down 200; 20.4uM; HL60; HT_HG-U133A	NR1H2 RPL37A ZMYND8	6.50e-04	187	21	3	3075_DN
Drug	17-AAG; Up 200; 1uM; PC3; HT_HG-U133A	LIPG RPL37A ESRRG	6.50e-04	187	21	3	1218_UP
Drug	Lidocaone hydrochloride [73-78-9]; Down 200; 14.8uM; MCF7; HT_HG-U133A	KMT2A KDM4B ZMYND8	6.81e-04	190	21	3	4421_DN
Drug	AC1NDP1R	ESRRB ESRRG	6.82e-04	42	21	2	CID004629338
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A	CDC14B LIPG KDM4B	6.91e-04	191	21	3	4279_DN
Drug	Sanguinarine [2447-54-3]; Down 200; 12uM; MCF7; HT_HG-U133A	AKAP11 RPL37A ZMYND8	6.91e-04	191	21	3	4168_DN
Drug	Flutamide [13311-84-7]; Down 200; 14.4uM; PC3; HT_HG-U133A	LIPG ESRRG ZMYND8	6.91e-04	191	21	3	3803_DN
Drug	Beclomethasone dipropionate [5534-09-8]; Up 200; 7.6uM; PC3; HT_HG-U133A	LIPG ESRRG ZMYND8	6.91e-04	191	21	3	4580_UP
Drug	Dipyrone [5907-38-0]; Down 200; 12uM; MCF7; HT_HG-U133A	KMT2A CDC14B KDM4B	7.02e-04	192	21	3	3929_DN
Drug	exemestane	ESRRB ESRRG	7.15e-04	43	21	2	CID000060198
Drug	n-octylphenol	ESRRB ESRRG	7.15e-04	43	21	2	CID000013700
Drug	Guanfacine hydrochloride [29110-48-3]; Up 200; 14.2uM; PC3; HT_HG-U133A	LIPG ESRRG PTK7	7.23e-04	194	21	3	4660_UP
Drug	Ethynodiol diacetate [297-76-7]; Up 200; 10.4uM; MCF7; HT_HG-U133A	KMT2A CDC14B KDM4B	7.34e-04	195	21	3	5024_UP
Drug	Prednisone [53-03-2]; Up 200; 11.2uM; PC3; HT_HG-U133A	LIPG ESRRG ZMYND8	7.34e-04	195	21	3	4577_UP
Drug	Acenocoumarol [152-72-7]; Up 200; 11.4uM; PC3; HT_HG-U133A	CDC14B LIPG PTK7	7.34e-04	195	21	3	5878_UP
Drug	retinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A	CDC14B NR1H2 KDM4B	7.34e-04	195	21	3	6971_DN
Drug	Lidocaone hydrochloride [73-78-9]; Up 200; 14.8uM; HL60; HG-U133A	KMT2A CDC14B ZMYND8	7.45e-04	196	21	3	1999_UP
Drug	Chrysene-1,4-quinone [100900-16-1]; Down 200; 15.4uM; PC3; HT_HG-U133A	AKAP11 RPL37A PTK7	7.45e-04	196	21	3	7139_DN
Drug	Indapamide [26807-65-8]; Up 200; 10.6uM; PC3; HT_HG-U133A	KMT2A CDC14B ZMYND8	7.45e-04	196	21	3	4335_UP
Drug	lasofoxifene	ESRRB ESRRG	7.49e-04	44	21	2	CID000216416
Drug	ospemifene	ESRRB ESRRG	7.49e-04	44	21	2	CID003036505
Drug	Norgestrel-(-)-D [797-63-7]; Down 200; 12.8uM; PC3; HT_HG-U133A	CDC14B KDM4B ZMYND8	7.56e-04	197	21	3	3708_DN
Drug	Rapamycin; Up 200; 0.1uM; HL60; HT_HG-U133A	KMT2A CDC14B ESRRG	7.56e-04	197	21	3	6180_UP
Drug	Dizocilpine maleate [77086-22-7]; Down 200; 11.8uM; PC3; HT_HG-U133A	CDC14B LIPG ZMYND8	7.56e-04	197	21	3	5746_DN
Drug	Folic acid [59-30-3]; Down 200; 9uM; MCF7; HT_HG-U133A	CDC14B KDM4B ZMYND8	7.56e-04	197	21	3	7201_DN
Drug	Debrisoquin sulfate [581-88-4]; Up 200; 9uM; PC3; HT_HG-U133A	KMT2A LIPG ZMYND8	7.56e-04	197	21	3	6688_UP
Drug	sodium 4-phenylbutyrate; Up 200; 100uM; MCF7; HG-U133A	KMT2A ZMYM4 KDM4B	7.56e-04	197	21	3	341_UP
Drug	Estropipate [7280-37-7]; Up 200; 9.2uM; PC3; HT_HG-U133A	KMT2A KDM4B ZMYND8	7.68e-04	198	21	3	4472_UP
Drug	Amyleine hydrochloride [532-59-2]; Down 200; 14.8uM; MCF7; HT_HG-U133A	NR1H2 KDM4B ZMYND8	7.68e-04	198	21	3	1491_DN
Drug	Thioperamide maleate [106243-16-7]; Up 200; 9.8uM; PC3; HT_HG-U133A	KDM4B ESRRG PTK7	7.68e-04	198	21	3	4675_UP
Drug	Nitrofural [59-87-0]; Up 200; 20.2uM; PC3; HT_HG-U133A	CDC14B LIPG ESRRG	7.68e-04	198	21	3	6721_UP
Drug	Troleandomycin [2751-09-9]; Down 200; 5uM; HL60; HG-U133A	NR1H2 ZMYM4 RPL37A	7.79e-04	199	21	3	1965_DN
Drug	Iodipamide [606-17-7]; Up 200; 3.6uM; PC3; HT_HG-U133A	KMT2A LIPG KDM4B	7.79e-04	199	21	3	5085_UP
Drug	Demecarium bromide [56-94-0]; Up 200; 5.6uM; PC3; HT_HG-U133A	KDM4B ESRRG ZMYND8	7.79e-04	199	21	3	5795_UP
Drug	Cefoxitin sodium salt [33564-30-6]; Down 200; 8.8uM; PC3; HT_HG-U133A	ZMYM4 RPL37A PTK7	7.79e-04	199	21	3	7148_DN
Drug	Famprofazone [22881-35-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A	KMT2A CDC14B KDM4B	7.79e-04	199	21	3	3928_DN
Drug	Glycocholic acid [475-31-0]; Up 200; 8.6uM; HL60; HT_HG-U133A	CDC14B KDM4B ZMYND8	7.79e-04	199	21	3	2454_UP
Drug	Idazoxan hydrochloride [79944-56-2]; Down 200; 16.6uM; MCF7; HT_HG-U133A	CDC14B NR1H2 ZMYND8	7.79e-04	199	21	3	6465_DN
Drug	tetraethylenepentamine pentahydrochloride; Up 200; 100uM; MCF7; HG-U133A	KMT2A KDM4B ZMYND8	7.79e-04	199	21	3	406_UP
Drug	Moxonidine [75438-57-2]; Up 200; 16.6uM; PC3; HT_HG-U133A	KMT2A LIPG ESRRG	7.90e-04	200	21	3	4084_UP
Drug	chlorpropamide; Down 200; 100uM; MCF7; HG-U133A	ZMYM4 KDM4B USP33	7.90e-04	200	21	3	141_DN
Drug	Dextromethorphan hydrobromide monohydrate [6700-34-1]; Up 200; 10.8uM; HL60; HT_HG-U133A	KMT2A KDM4B ZMYND8	7.90e-04	200	21	3	1281_UP
Drug	triphenylethylene	ESRRB ESRRG	8.18e-04	46	21	2	CID000006025
Drug	4-octylphenol	ESRRB ESRRG	8.54e-04	47	21	2	CID000015730
Drug	Implanon	ESRRB ESRRG	8.54e-04	47	21	2	CID000040976
Disease	azoospermia (implicated_via_orthology)	ESRRB ESRRG	1.68e-04	27	21	2	DOID:14227 (implicated_via_orthology)
Disease	response to TNF antagonist	GFRA1 RPL37A	6.75e-04	54	21	2	EFO_0004653
Disease	vascular endothelial growth factor measurement	NR1H2 PTK7	7.26e-04	56	21	2	EFO_0004762
Disease	congenital heart disease (implicated_via_orthology)	KMT2A RNF20	1.10e-03	69	21	2	DOID:1682 (implicated_via_orthology)
Disease	susceptibility to plantar warts measurement	KDM4B ESRRB	1.86e-03	90	21	2	EFO_0008406
Disease	Neurodevelopmental Disorders	KMT2A PTK7	1.98e-03	93	21	2	C1535926
Disease	sleep duration	KMT2A ZMYM4 ESRRG	2.07e-03	362	21	3	EFO_0005271
Disease	insomnia measurement	KMT2A KDM4B ZMYND8	3.66e-03	443	21	3	EFO_0007876
Disease	breast cancer (is_implicated_in)	KDM4B RNF20	5.06e-03	150	21	2	DOID:1612 (is_implicated_in)
Disease	prostate cancer (is_marker_for)	KMT2A KDM4B	5.46e-03	156	21	2	DOID:10283 (is_marker_for)

Protein segments in the cluster

Peptide	Gene	Start	Entry
YKARLTCPCCNMRKK	RNF20	916	Q5VTR2
MVYRYCCKINKKLKS	CDC14B	96	O60729
KVRNCMLFKQKKNSC	AKAP11	1276	Q9UKA4
MVYRYCCKINKKLKS	CDC14C	66	A4D256
QRWKLKCVYCRKRMK	KDM4B	846	O94953
KCVYCRKRMKKVSGA	KDM4B	851	O94953
CNSIGYNAKKMRNKR	LIPG	316	Q9Y5X9
KYTCSFCGKTKMKRR	RPL37A	36	P61513
KRCEEMKYCKKQCRR	MLKL	16	Q8NB16
QKSLYNCRCKRGMKK	GFRA1	81	P56159
NCRCKRGMKKEKNCL	GFRA1	86	P56159
RRKSCQACRFMKCLK	ESRRG	176	P62508
MKNKACRKNLSKGYN	LINC00305	76	Q7Z4B0
GRNIKKQCCKMRKCQ	KMT2A	1181	Q03164
RRKSCQACRFMKCLK	ESRRB	151	O95718
ACQMKATGKLYACKK	GRK1	206	Q15835
CTLEKNAKKKMYGCT	ZMYND8	196	Q9ULU4
FMRRKCQQCRLRKCK	NR1H2	136	P55055
YCLCKKQRKRSRTGM	RNF217	526	Q8TC41
QRMHRGKKVYKCKEC	ZNF660	181	Q6AZW8
GLMFYCKKRCKAKRL	PTK7	721	Q13308
YQMAKCDACKRQGKL	ZMYM4	811	Q5VZL5
NMYSCEKCKKLRNGV	USP33	586	Q8TEY7